logo
ProjectActive

MS Pharma

The status, timeline and source of this project. A free account opens every field.

Source: International Finance Corporation (IFC)

The proposed project involves an IFC equity investment of up US$ 50 million in MS Pharma Ventures Holding W.L.L. (“MS-Pharma” or “the group”), a Jordan based generic pharmaceutical manufacturer and distributor across the Middle East and North Africa (MENA) region.   The investment will allow MS-Pharma to continue increasing its geographical reach in the region mainly via mergers and acquisitions o

Status
Prospective
Sector
Commercial, Manufacturing (Industrial), Government, Hospital
Location
Jordan
Updated
22 Jul 2026
Source
International Finance Corporation (IFC)

ConstructChat

Ask ConstructChat about MS Pharma

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “MS Pharma” is an infrastructure initiative in the Commercial sector, located in Jordan. Taiyo aggregates data on it from International Finance Corporation (IFC).

Participants

Sponsoring Agency

Status

Original status

active

Taiyo status

Prospective

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

The proposed project involves an IFC equity investment of up US$ 50 million in MS Pharma Ventures Holding W.L.L. (“MS-Pharma” or “the group”), a Jordan based generic pharmaceutical manufacturer and distributor across the Middle East and North Africa (MENA) region.   The investment will allow MS-Pharma to continue increasing its geographical reach in the region mainly via mergers and acquisitions of manufacturing assets in new markets or construction of new facilities (Saudi Arabia). Short-term plans include upgrading the MS-Pharma injectable plant (MSI) in Jordan and MS Pharma Injectable plant in Turkey (acquired in 2012 and 2016 respectively), expanding the El Kendi manufacturing facility in Algeria to double production capacity, and pursue acquisition of product portfolio/marketing authorizations to accelerate market entry (Egypt).  In Saudi Arabia the group has acquired in the private market an area, within a pharmacological industrial park, where it plans to build a production facility and worker accommodations. In Algeria, the group, via the controlled El Kendi Pharma Manufacturing, will expand its production by building, within the same property where the existing plant is located, a new 4-story facility with a 1,750-m2 footprint and a total floor space on 7,000 m2.  MS-Pharma activities date back to 1989 when the first company, United Pharmaceutical (UNP), and its production plant was established in Amman, Jordan.  The group, a limited liability company incorporated in the Kingdom of Bahrain, specializes in generic pharmaceutical products for five therapeutic areas: cardiology, central nervous system, respiratory, oncology and anti-inflammatory.  It consolidates manufacture and trade of both branded and unbranded products in 11 countries across MENA.

Original sector

G-FA - Pharmaceuticals and Medicine

Location

Country

Jordan

Source

Source

International Finance Corporation (IFC)

URL

More Details

Record type

Project

Sector

Commercial, Manufacturing (Industrial), Government, Hospital

Article published date

2025-09-10

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project